Q1 2024 Earnings Estimate for BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Issued By HC Wainwright

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) – Research analysts at HC Wainwright upped their Q1 2024 earnings per share (EPS) estimates for shares of BioXcel Therapeutics in a note issued to investors on Monday, April 15th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of ($0.69) for the quarter, up from their prior forecast of ($0.93). HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for BioXcel Therapeutics’ current full-year earnings is ($2.52) per share. HC Wainwright also issued estimates for BioXcel Therapeutics’ Q2 2024 earnings at ($0.63) EPS, Q3 2024 earnings at ($0.59) EPS, Q4 2024 earnings at ($0.54) EPS and FY2024 earnings at ($2.42) EPS.

Other analysts have also issued research reports about the stock. UBS Group reiterated a “neutral” rating and set a $4.00 target price (down previously from $9.00) on shares of BioXcel Therapeutics in a research note on Wednesday, February 21st. Bank of America dropped their price objective on shares of BioXcel Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a research note on Wednesday, March 13th. Finally, Canaccord Genuity Group lowered their target price on BioXcel Therapeutics from $18.00 to $7.00 and set a “buy” rating for the company in a report on Thursday, March 14th. Four research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $16.86.

BioXcel Therapeutics Trading Down 1.5 %

BTAI stock opened at $2.55 on Thursday. The stock’s 50 day simple moving average is $2.88 and its 200 day simple moving average is $3.17. BioXcel Therapeutics has a 12-month low of $1.91 and a 12-month high of $29.56. The firm has a market cap of $77.98 million, a P/E ratio of -0.41 and a beta of 0.40.

BioXcel Therapeutics (NASDAQ:BTAI) last issued its quarterly earnings data on Tuesday, March 12th. The company reported ($0.76) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.98) by $0.22. The firm had revenue of $0.38 million during the quarter, compared to analyst estimates of $1.17 million. BioXcel Therapeutics had a negative return on equity of 890.63% and a negative net margin of 12,974.86%.

Institutional Trading of BioXcel Therapeutics

Several hedge funds have recently bought and sold shares of the company. Charles Schwab Investment Management Inc. increased its stake in BioXcel Therapeutics by 0.4% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 143,893 shares of the company’s stock valued at $2,685,000 after buying an additional 611 shares during the period. Legal & General Group Plc increased its stake in shares of BioXcel Therapeutics by 7.5% during the fourth quarter. Legal & General Group Plc now owns 9,678 shares of the company’s stock valued at $208,000 after acquiring an additional 678 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in BioXcel Therapeutics by 5.7% during the second quarter. Price T Rowe Associates Inc. MD now owns 14,747 shares of the company’s stock worth $195,000 after purchasing an additional 794 shares in the last quarter. JPMorgan Chase & Co. lifted its position in BioXcel Therapeutics by 9.5% in the fourth quarter. JPMorgan Chase & Co. now owns 11,595 shares of the company’s stock worth $249,000 after purchasing an additional 1,006 shares during the period. Finally, Tower Research Capital LLC TRC boosted its stake in BioXcel Therapeutics by 205.2% during the 1st quarter. Tower Research Capital LLC TRC now owns 1,529 shares of the company’s stock valued at $29,000 after purchasing an additional 1,028 shares in the last quarter. 30.68% of the stock is currently owned by institutional investors.

About BioXcel Therapeutics

BioXcel Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.